Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04653766
Recruitment Status : Active, not recruiting
First Posted : December 4, 2020
Results First Posted : May 27, 2021
Last Update Posted : May 27, 2021
Sponsor:
Information provided by (Responsible Party):
Bioxodes S.A.

Brief Summary:
The purpose of this First-in-Human study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of Ir-CPI, a novel dual inhibitor of FXIIa and FXIa, following IV administration of single ascending doses in healthy male volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: Ir-CPI - Dose 1 Drug: Ir-CPI - Dose 2 Drug: Ir-CPI - Dose 3 Drug: Ir-CPI - Dose 4 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: A Phase I, Double Blind, Placebo Controlled, Single Ascending Dose Study of Intravenously Administered Ir-CPI to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability in Healthy Male Volunteers
Actual Study Start Date : September 12, 2019
Actual Primary Completion Date : July 18, 2020
Estimated Study Completion Date : July 2025

Arm Intervention/treatment
Experimental: Ir-CPI - Dose 1
Participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
Drug: Ir-CPI - Dose 1
6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours

Experimental: Ir-CPI - Dose 2
Participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
Drug: Ir-CPI - Dose 2
6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours

Experimental: Ir-CPI - Dose 3
Participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
Drug: Ir-CPI - Dose 3
6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours

Experimental: Ir-CPI - Dose 4
Participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
Drug: Ir-CPI - Dose 4
6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours

Placebo Comparator: Placebo
Participants received a single intravenous dose of placebo during 6 hours
Drug: Placebo
For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).




Primary Outcome Measures :
  1. Measurement of the Safety Lab Parameter Activated Partial Thromboplastin Time (aPTT) [ Time Frame: From pre-dose (baseline / Day 1) up to the discharge visit (Day 10 ± 2 days) ]
    These safety aPTT results were readily available to the PI for safety follow-up during and after the study drug administration. Safety aPTT was followed up "at the bedside" at regular time-points (as opposed to the PD biomarker aPTT, which was assessed by the central laboratory alongside the PK time-points). An aPTT ratio was calculated by dividing the aPTT value (in sec) of the specific time-point (aPTTt) by the baseline aPTT value (in sec) (aPTTbaseline) of the same participant (aPTT ratio = aPTTt/aPTTbaseline). The baseline time-point was considered as having an aPTT ratio of 1.


Secondary Outcome Measures :
  1. Measurement of the Maximum Plasma Concentration (Cmax) of Ir-CPI [ Time Frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72, 96, 144 hours (144 hours for Dose 4 only) ]
    Pharmacokinetic set (PKS): all of the included participants who were administered a complete infusion of study drug without major protocol deviation affecting PK evaluation.

  2. Measurement of the Time to Reach Maximum Plasma Concentration (Tmax) of Ir-CPI [ Time Frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72, 96, 144 hours (144 hours for Dose 4 only) ]
    Pharmacokinetic set (PKS): all of the included participants who were administered a complete infusion of study drug without major protocol deviation affecting PK evaluation.

  3. Measurement of the Area Under the Plasma Concentration-time Curve From Time Zero to 6h (AUC0-6) and From Time Zero to Time of Infinity (AUCinf) [ Time Frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72, 96, 144 hours (144 hours for Dose 4 only) ]
    Pharmacokinetic set (PKS): all of the included participants who were administered a complete infusion of study drug without major protocol deviation affecting PK evaluation.

  4. Measurement of the Effect of Ir-CPI on the Activated Partial Thromboplastin Time (aPTT) [ Time Frame: Pre-dose (baseline / Day 1) up to discharge visit (Day 10 ± 2 days) ]
    The activated partial thromboplastin time (aPTT) is used as a pharmacodynamic marker. No data were available for the Ir-CPI 1.5 mg/kg group because the results were not usable due to plasma preparation and method repeatability problems. An aPTT ratio was calculated by dividing the aPTT value (in sec) of the specific time-point (aPTTt) by the baseline aPTT value (in sec) (aPTTbaseline) of the same participant (aPTT ratio = aPTTt/aPTTbaseline). The baseline time-point (Day 1 H00:00) was considered as having an aPTT ratio of 1.

  5. Measurement of the Effect of Ir-CPI on Factor XI Activity [ Time Frame: Pre-dose (baseline / Day 1) up to discharge visit (Day 10 ± 2 days) ]
    This analysis was performed on the Pharmacodyamic Set (PDS): all of the included participants who completed the study without any protocol deviation affecting PD evaluation and with at least one available post-baseline PD data point.

  6. Measurement of the Effect of Ir-CPI on Factor XII Activity [ Time Frame: Pre-dose (baseline / Day 1) up to discharge visit (Day 10 ± 2 days) ]
    This analysis was performed on the Pharmacodyamic Set (PDS): all of the included participants who completed the study without any protocol deviation affecting PD evaluation and with at least one available post-baseline PD data point.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Participants must satisfy all of the following inclusion criteria before being allowed to enter the study:

  1. Have given written informed consent approved by the relevant Ethics Committee (EC) governing the site, indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
  2. Male participants between 18 and 55 years of age, inclusive at screening.
  3. Otherwise healthy with no clinically significant abnormalities as determined by medical history, physical examination, blood chemistry assessments, haematological assessments, coagulation and urinalysis, measurement of vital signs, and ECG. Isolated out-of-range values judged by the PI (or designated physician) to be of no clinical significance can be allowed. This determination must be recorded in the participant's source documents.
  4. Have a body weight in the range of 50 to 90 kg inclusive at screening. Have a body mass index (BMI) of 19 to 28 kg/m2 inclusive at screening.
  5. Agree to abstain from alcohol intake 24 hours before administration of study drug, during the in-patient period of the study and 24 hours prior to all other ambulatory visits, up until and including the discharge visit.
  6. Agree not to use prescription medications within 14 days prior to study drug administration and through the duration of the study, unless approved by the PI and Sponsor medical monitor.
  7. Non-smokers or abstinence from tobacco or nicotine-containing products for at least 3 months prior to screening.
  8. Agree not to use over-the-counter (OTC) medications [including decongestants, antihistamines, and herbal medication (including herbal tea and St. John's Wort)], within 14 days prior to study drug administration through the discharge visit, unless approved by the PI and Sponsor medical monitor. Occasional use of paracetamol at recommended doses is allowed. Special rules apply for aspirin, corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDS (see exclusion criteria 6-7-8-9)
  9. Venous access (both arms) sufficient to allow blood sampling and study drug administration as per protocol.
  10. Participants and their partners of childbearing potential [meaning who are not surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (absence of menstrual periods for at least 12 consecutive months)] must be willing to use 2 methods of contraception: - a highly effective method of birth control starting at screening. Highly effective methods of birth control are defined as those that result in a low failure rate (i.e. Pearl Index less than 1% per year) when used consistently and correctly, such as implants, rings, patches, injectable or combined oral contraceptives, intrauterine devices (IUDs), or sexual abstinence (periodic abstinence e.g. calendar, ovulation, symptothermal, postovulation methods, declaration of abstinence for the duration of the trial, and withdrawal are not acceptable methods of contraception) . - and a local barrier form of contraception. Acceptable barrier methods are either the participant's use of a condom or the partner's use of an occlusive cap or diaphragm, or spermicides. Participants will not donate sperm from the selection visit and up to 90 days after the infusion. In case of sterile or vasectomised participants, no contraception will be required for their partners of childbearing potential.
  11. Willing/able to adhere to the study visit schedule and other requirements, prohibitions and restrictions specified in this protocol.

Exclusion Criteria:

If any of the following exclusion criteria apply, the participant must not enter the study:

  1. Currently have or have a history of any clinically significant medical illness or medical disorders the PI considers should exclude the participant, including (but not limited to) cardiovascular disease, neuromuscular, haematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.
  2. History of personal or familial bleeding disorders; including prolonged or unusual bleeding.
  3. History of deficiency in factor XII (FXII) or haemophilia type A (FVII) or type B (FIX) or type C (FXI).
  4. History of cerebral bleeding (e.g. after a car accident), stroke and cerebrovascular accident (CVA).
  5. Anamnestic history of Lyme disease or tick-borne encephalitis.
  6. Use of Acetylsalicylic-Acid (ASA)-containing OTC medications within 1 month prior to screening.
  7. Chronic administration of NSAIDs, chronic use of corticosteroids within 1 month prior to screening.
  8. Chronic administration of clopidogrel, ticlopidin, dipyridamole, Coumadin-like anticoagulants, new oral anticoagulant dabigatran, rivaroxaban, apixaban or edoxaban within 3 months prior to screening.
  9. Administration of unfractionated heparin, low molecular weight heparin, fibrinolytic agents and anti-FXa within 3 months prior to screening.
  10. Have an active acute or chronic infection or diagnosed latent infection.
  11. Systolic blood pressure (SBP) greater than 150 or less than 90 mmHg, diastolic blood pressure (DBP) greater than 90 or less than 50 mmHg, and heart rate (HR) greater than 100 or less than 40 bpm.
  12. Acute clinically relevant illness within 7 days prior to study drug administration or have had a major illness or hospitalisation within 1 month prior to study drug administration.
  13. Major or traumatic surgery within 12 weeks of screening.
  14. Any participant who plans to undergo elective surgery within 4 weeks prior to study drug administration and through the discharge visit.
  15. Positive serology test for HIV antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies at screening.
  16. Recent history (within previous 6 months) of alcohol or drug abuse.
  17. Have positive urine toxicology screen at screening or D -1 for substances of abuse including amphetamines, benzodiazepine, cocaine, opiates, barbiturate and cannabinoids.
  18. Have a positive alcohol breath test at screening or D-1.
  19. Consumes, on average, more than approximately 500 mg/day of caffeine (as contained in 5 cups of tea or coffee or 8 cans of caffeine-containing soda or other caffeinated products per day).
  20. Donated blood (i.e. 500 mL) within 3 months before D1.
  21. Have a history of active drug and/or food allergy or other active allergic disease requiring the constant use of medications, or a history of severe allergic reaction, angioedema or anaphylaxis.
  22. Received any other experimental therapy or new investigational drug within 30 days or 5 half-lives (whichever is longer) of study drug administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04653766


Locations
Layout table for location information
Belgium
A.T.C. Pharma
Liège, Belgium, 4000
Sponsors and Collaborators
Bioxodes S.A.
  Study Documents (Full-Text)

Documents provided by Bioxodes S.A.:
Study Protocol  [PDF] October 15, 2020
Statistical Analysis Plan  [PDF] July 9, 2020

Layout table for additonal information
Responsible Party: Bioxodes S.A.
ClinicalTrials.gov Identifier: NCT04653766    
Other Study ID Numbers: Clin_IrCPI_101
2019-002305-22 ( EudraCT Number )
First Posted: December 4, 2020    Key Record Dates
Results First Posted: May 27, 2021
Last Update Posted: May 27, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bioxodes S.A.:
Antithrombotic
Intrinsic coagulation pathway